News
(RTTNews) - INmune Bio, Inc. (INMB), on Tuesday presented baseline demographics and disease characteristics of participants in its MINDFuL Phase II clinical trial at the AD/PD 2025 Conference in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback